Eezer Goode? Subjective experiences of emerging psychoactive substances
Matthews, AJ and Bruno, RB, Eezer Goode? Subjective experiences of emerging psychoactive substances, Drug and Alcohol Review, 18-21 November 2012, Melbourne, Victoria, pp. 51. ISSN 0959-5236 (2012) [Conference Extract]
Issue: Emerging psychoactive substances (EPS) are relatively new
substances that have not been formally studied or are still being
researched. As such, little is known about the effects and risks of
using these drugs and there have been few animal or human toxicology
studies examining issues such as acute adverse events, drug
interactions, long-term health impacts or addiction. Data from
the Ecstasy and Related Drugs Reporting System, an annual national
Australian drug market monitoring system, has indicated increased
use of EPS substances among regular ecstasy using cohorts in
recent years. The EPS most commonly used by these participants
include psychedelic phenethylamines (2CI, 2CB, 2CE) and the
stimulants 4-methylmethcathinone (mephedrone) and methylone
Approach: Participants interviewed in the 2012 Ecstasy and
Related Drugs Reporting System were asked to provide subjective
ratings on the EPS that they had used in the last six months.
Participants rated the pleasurable effects and the negative effects
(both acute and longer-term) of each drug on the last occasion
of use and also rated the likelihood that they would use the drug
Key Findings: Ratings in relation to EPS were compared to those
of more commonly used drugs such as ecstasy, cocaine and LSD
revealing interesting similarities and differences in subjective profi les.
Implications: These fi ndings have important implications for
understanding the use and abuse potential for emerging substances
in the psychostimulant drug market.
Conclusion: Given the substantially greater dependence potential
of some substances (e.g. cocaine and mephedrone) in comparison to
ecstasy, careful monitoring of consumption changes in these
demographics is warranted.